Your Messages Inbox
Your Article Summary
See Latest ArticlesGenentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Genentech, 05/20/09
Genentech, Inc. and Biogen Idec announced that the companies submitted two supplemental Biologics License Applications to the U.S. Food and Drug Administration for Rituxan plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia. The companies will request a priority review, and if granted, anticipate the FDA will make a decision within six months.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Zoster vaccination: A new opportunity for adult immunization
Canadian Journal of Infectious Diseases, 12/15/09
FDA Approves Newly Revised Prescribing Information For Azilect Reducing Medication And Food Restrictions
Teva Pharmaceutical Industries, 12/15/09
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
Article Search
Sponsor